These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2675109)

  • 21. [Histologic findings on the iron deposits in duodenal mucosa of major thalassemia patients].
    Rizzioni G; Taverna PL; Astaldi G
    Minerva Pediatr; 1970 Feb; 22(4):261-5. PubMed ID: 5434900
    [No Abstract]   [Full Text] [Related]  

  • 22. Iron overload in a non-transfused patient with thalassaemia intermedia.
    Celada A
    Scand J Haematol; 1982 Feb; 28(2):169-74. PubMed ID: 7089477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Erythrokinetics and splenic function in thalassemic syndromes].
    Torlontano G; Tata A; Proietti M
    Recenti Prog Med; 1971 Mar; 50(3):246-71. PubMed ID: 5109833
    [No Abstract]   [Full Text] [Related]  

  • 24. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron-related disturbances of cell-mediated immunity in multitransfused children with thalassemia major.
    Pardalos G; Kanakoudi-Tsakalidis F; Malaka-Zafiriu M; Tsantali H; Athanasiou-Metaxa M; Kallinikos G; Papaevangelou G
    Clin Exp Immunol; 1987 Apr; 68(1):138-45. PubMed ID: 3498564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic iron stores in thalassemia: non-invasive magnetic measurements.
    Brittenham GM; Allen CJ; Farrell DE; Harris JW
    Prog Clin Biol Res; 1989; 309():101-6. PubMed ID: 2780744
    [No Abstract]   [Full Text] [Related]  

  • 27. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
    Mazza P; Giua R; De Marco S; Bonetti MG; Amurri B; Masi C; Lazzari G; Rizzo C; Cervellera M; Peluso A
    Haematologica; 1995; 80(5):398-404. PubMed ID: 8566878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron balance and the management of iron overload in beta-thalassemia intermedia.
    Pippard MJ; Weatherall DJ
    Birth Defects Orig Artic Ser; 1988; 23(5B):29-33. PubMed ID: 3390555
    [No Abstract]   [Full Text] [Related]  

  • 29. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major.
    Kattamis A; Papassotiriou I; Palaiologou D; Apostolakou F; Galani A; Ladis V; Sakellaropoulos N; Papanikolaou G
    Haematologica; 2006 Jun; 91(6):809-12. PubMed ID: 16769583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of desferrioxamine on iron elimination in children after multiple transfusions].
    Leggio ML
    Minerva Pediatr; 1966 Feb; 18(3):101-3. PubMed ID: 5930397
    [No Abstract]   [Full Text] [Related]  

  • 31. Mechanisms and regulation of intestinal iron absorption.
    Peters TJ; Raja KB; Simpson RJ; Snape S
    Ann N Y Acad Sci; 1988; 526():141-7. PubMed ID: 3291678
    [No Abstract]   [Full Text] [Related]  

  • 32. [Iron absorption in HbH disease].
    Lin CK; Lin JS; Chen SY; Lo JG; Chien CC; Liu RS; Jiang MC; Lee SH
    Zhonghua Yi Xue Za Zhi (Taipei); 1992 Feb; 49(2):76-80. PubMed ID: 1315200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disorders of iron metabolism in geriatrics.
    Ho R
    Geriatrics; 1968 Jul; 23(7):79-86. PubMed ID: 5658992
    [No Abstract]   [Full Text] [Related]  

  • 34. Protein antioxidants in thalassemia.
    Awadallah S
    Adv Clin Chem; 2013; 60():85-128. PubMed ID: 23724742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation and selection of patients for "substitutive-inhibitory therapy" in thalassemia and sickle cell disease.
    Rewald E
    Isr J Med Sci; 1965 Jul; 1(4):782-3. PubMed ID: 5856119
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia.
    Meloni A; Ramazzotti A; Positano V; Salvatori C; Mangione M; Marcheschi P; Favilli B; De Marchi D; Prato S; Pepe A; Sallustio G; Centra M; Santarelli MF; Lombardi M; Landini L
    Int J Med Inform; 2009 Aug; 78(8):503-12. PubMed ID: 19345609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S; Cossu P; Toccafondi C; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Loi A; Bertolino F; Cao A
    Am J Pediatr Hematol Oncol; 1983; 5(1):73-7. PubMed ID: 6859457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal calcium transport and its regulation in thalassemia: interaction between calcium and iron metabolism.
    Lertsuwan K; Wongdee K; Teerapornpuntakit J; Charoenphandhu N
    J Physiol Sci; 2018 May; 68(3):221-232. PubMed ID: 29484538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 40. Partial splenic embolization in patients with thalassemia major.
    Politis C; Spigos D; Georgiopoulou P; Vrettou E; Economidou J; Karamerou A; Richardson C; Papaevangelou G
    Birth Defects Orig Artic Ser; 1988; 23(5B):275-82. PubMed ID: 3390552
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.